Candel Therapeutics (CADL) Free Cash Flow (2020 - 2025)

Candel Therapeutics has disclosed Free Cash Flow across 6 years of filings, most recently posting -$10.5 million for Q4 2025.

• Free Cash Flow for Q4 2025 came in at -$10.5 million, down 80.57% year-over-year; the trailing twelve-month figure through Dec 2025 was -$38.4 million (down 42.18% YoY), and the FY2025 annual result was -$38.4 million, down 42.18% from the prior year.
• Free Cash Flow came in at -$10.5 million for Q4 2025 at Candel Therapeutics, down from -$10.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$3.5 million in Q2 2021 to a low of -$10.9 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$7.5 million (2021), against an average of -$7.8 million.
• Across the five-year window, Free Cash Flow slumped 470.56% in 2021 and climbed 26.35% in 2024, its largest moves.
• Candel Therapeutics' Free Cash Flow stood at -$5.7 million in 2021, then dropped by 16.56% to -$6.7 million in 2022, then declined by 11.59% to -$7.5 million in 2023, then gained by 21.98% to -$5.8 million in 2024, then plunged by 80.57% to -$10.5 million in 2025.
• The last three Free Cash Flow figures came in at -$10.5 million (Q4 2025), -$10.4 million (Q3 2025), and -$8.9 million (Q2 2025), per Business Quant data.